Form 4: Intuitive Surgical Executive VP Marshall Mohr Executes Stock Options and Sells Shares Under 10b5-1 Trading Plan

Sentiment:

SEC Form 4


Executive VP of Global Business at Intuitive Surgical, Marshall Mohr, exercised stock options and sold shares of common stock on February 28 and 29, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

  • Marshall Mohr, Executive VP of Global Business at Intuitive Surgical, engaged in transactions involving the company's common stock on February 28 and 29, 2024.
  • These transactions included the exercise of non-qualified stock options and restricted stock units (RSUs), as well as the sale of common stock.
  • The sales were executed under a pre-arranged trading plan that complies with SEC Rule 10b5-1, which expires on November 15, 2024.
  • On February 28, 2024, Mohr exercised options to acquire a total of 95,260 shares at prices ranging from $76.9989 to $242.3367.
  • Also on February 28, 2024, Mohr sold a total of 84,780 shares at a weighted average price of approximately $385.0805.
  • On February 29, 2024, Mohr exercised 3,256 RSUs and sold 1,651 shares to cover statutory tax withholding requirements.
  • Following these transactions, Mohr directly owns 49,502 shares of common stock and indirectly owns 100,353 shares through a trust.
  • Mohr also holds non-qualified stock options for various amounts of shares at exercise prices ranging from $76.9989 to $242.3367, expiring between 2026 and 2030.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports transactions related to stock options and share sales by an executive. The use of a 10b5-1 plan suggests a planned approach, mitigating potential negative interpretations.

Positives

  • The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a common and legal practice for corporate insiders to sell shares without being accused of insider trading.
  • The exercise of stock options and RSUs indicates Mohr's belief in the long-term value of the company.

Negatives

  • The sale of a significant number of shares by an executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

  • The market price of Intuitive Surgical's stock could be affected by large sales of shares, even if they are part of a pre-arranged plan.
  • Changes in the company's performance or market conditions could impact the value of the remaining shares and stock options held by Mohr.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but it does indicate that the executive will continue to sell shares under the 10b5-1 trading plan until its expiration on November 15, 2024.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan is a standard practice to avoid insider trading accusations. Investors often monitor these transactions to gain insights into management's perspective on the company's value.

Comparison to Industry Standards

  • Executive compensation practices, including stock options and RSUs, are common in the medical device industry.
  • Companies like Stryker, Medtronic, and Johnson & Johnson also utilize stock-based compensation to align executive interests with shareholder value.
  • The vesting schedules and exercise prices of the options are within typical ranges for executive compensation packages in comparable companies.
  • The use of a 10b5-1 trading plan is a standard practice among executives at publicly traded companies to manage their stock holdings.

Stakeholder Impact

  • Shareholders may be interested in the executive's transactions as an indicator of management's confidence in the company.
  • Employees may be affected by the perceived value of their own stock options and RSUs.
  • The transactions have no direct impact on customers, suppliers, or creditors.

Next Steps

  • Continued monitoring of executive stock transactions.
  • Observation of the impact of these transactions on the stock price.
  • Review of future SEC filings related to insider trading activity.

Key Dates

DateDescription
02/28/2024Date of multiple transactions involving the exercise of stock options and sale of common stock.
02/29/2024Date of RSU exercise and share sales to cover tax withholding.
November 15, 2024Expiration date of the 10b5-1 trading plan.
08/15/2026Expiration date of some non-qualified stock options.
02/15/2027Expiration date of some non-qualified stock options.
08/15/2027Expiration date of some non-qualified stock options.
02/15/2028Expiration date of some non-qualified stock options.
08/15/2028Expiration date of some non-qualified stock options.
02/15/2029Expiration date of some non-qualified stock options.
08/15/2029Expiration date of some non-qualified stock options.
02/28/2030Expiration date of some non-qualified stock options.
08/28/2030Expiration date of some non-qualified stock options.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.